Santen Pharmaceutical Co., Ltd. announced that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an out-licensing agreement with Visiox Pharmaceuticals Inc. (hereafter Visiox) on the rights to product manufacturing, commercialization, and sales of OMLONTI®, an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Under the terms of the agreement, Santen grants Visiox exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI.

Santen is eligible to receive sales milestone payments, as well as royalties on net U.S. sales of OMLONTI.